Simulations Plus Reports First Quarter FY2018 Financial Results

Consolidated net income up 26.0%; diluted earnings per share increased 22.8%

LANCASTER, Calif.--()--Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its first quarter of fiscal year 2018, the period ended November 30, 2017 (1QFY18).

1QFY18 highlights compared with 1QFY17:

  • Net revenues increased 30.5%, or $1.7 million, to a new first quarter record $7.1 million vs. $5.4 million
  • Gross profit increased 30.6%, or $1.3 million, to $5.3 million from $4.1 million
  • SG&A was $2.4 million, an increase of 29.2%, or $545,000, from $1.9 million
  • SG&A as a percentage of revenues decreased slightly to 34.1% from 34.4%
  • Income before taxes increased $550,000, or 27.9%, to $2.5 million from $2.0 million
  • Net income increased $354,000, or 26.0%, to $1.7 million from $1.4 million
  • Diluted earnings per share increased 22.8%, or $0.02, to $0.10 from $0.08 per share

John Kneisel, chief financial officer of Simulations Plus, said, “Revenue growth in our core divisions in Lancaster and Buffalo coupled with the new revenues and profits from DILIsym Services acquired in the last quarter of our prior fiscal year produced a 26% growth in net income and a two-cent growth in EPS, resulting in a strong start to the new fiscal year.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added, “We’re very pleased to report these first quarter results for fiscal year 2018, which begins the first full fiscal year after our acquisition of DILIsym Services, Inc., in June of last year. This is yet another record quarter, setting an all-time record for revenues for any quarter at over $7 million, and record high earnings for a first fiscal quarter. We continue to push forward the cutting edge of simulation and modeling for pharmaceutical research, and it is clear that the industry continues to adopt simulation and modeling tools at a steady pace in its effort to increase productivity and decrease overall costs of bringing new medicines to market for all of us.”

Investor Conference Call

The Company has announced an investor conference call that will be webcast live at 1:15 p.m. PST/4:15 p.m. EST on Tuesday, January 9, 2018. All interested parties are invited to join the call by registering here. On registering, you will receive a confirmation e-mail with instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (562) 247-8321, and enter access code 336-145-278. A replay will be available on the Simulations Plus website following the call.

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of our new software products as well as improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

Follow us on Twitter | LinkedIn



As of

    (Unaudited)     (Audited)
November 30,     August 31,



Current assets
Cash and cash equivalents $ 7,045,756 $ 6,215,718
Accounts receivable, net of allowance for doubtful accounts of $0 5,230,824 4,048,725
Revenues in excess of billings 1,361,242 1,481,082
Prepaid income taxes - 462,443
Prepaid expenses and other current assets   348,708   459,902
Total current assets 13,986,530 12,667,870
Long-term assets
Capitalized computer software development costs,
net of accumulated amortization of $10,080,778 and $9,795,469 4,529,380 4,307,600
Property and equipment, net 305,634 291,135
Intellectual property, net of accumulated amortization of $2,326,459 and $2,095,417 6,598,541 6,829,583
Other intangible assets net of accumulated amortization of $584,375 and $495,000 3,905,625 3,995,000
Goodwill 10,387,198 10,387,198
Other assets   37,227   34,082
Total assets $ 39,750,135 $ 38,512,468
Current liabilities
Accounts payable $ 141,815 $ 240,892
Accrued payroll and other expenses 1,085,065 983,293
Income taxes payable 404,600 -
Current portion - Contracts payable 3,150,000 247,328
Billings in excess of revenues 602,233 216,958
Deferred revenue   270,250   353,962
Total current liabilities 5,653,963 2,042,433
Long-term liabilities
Deferred income taxes,net 4,791,460 4,926,960
Payments due under Contracts payable   2,626,376   5,738,188
Total liabilities 13,071,799 12,707,581
Commitments and contingencies
Shareholders' equity
Preferred stock, $0.001 par value
10,000,000 shares authorized
no shares issued and outstanding $ - $ -
Common stock, $0.001 par value
50,000,000 shares authorized
17,287,652 and 17,277,604 shares issued and outstanding 7,288 7,278
Additional paid-in capital 12,303,662 12,109,141
Retained earnings   14,367,386   13,688,468
Total shareholders' equity


26,678,336 $ 25,804,887
Total liabilities and shareholders' equity $ 39,750,135 $ 38,512,468



For the three months ended November 30,






Net Revenues

$ 7,068,782 $ 5,417,933
Cost of revenues   1,735,608     1,335,982  
Gross margin   5,333,174     4,081,951  
Operating expenses
Selling, general, and administrative 2,408,514 1,863,555
Research and development   360,817     290,299  
Total operating expenses   2,769,331     2,153,854  
Income from operations   2,563,843     1,928,097  
Other income (expense)
Interest income 4,310 4,455
Interest expense (38,470 ) -
Gain(loss) on currency exchange   (12,678 )   34,928  
Total other income (expense)   (46,838 )   39,383  
Income before provision for income taxes 2,517,005 1,967,480
Provision for income taxes   (800,999 )   (605,915 )
Net Income $ 1,716,006   $ 1,361,565  
Earnings per share
Basic $ 0.10 $ 0.08
Diluted $ 0.10 $ 0.08
Weighted-average common shares outstanding
Basic 17,282,132 17,226,192
Diluted 17,859,683 17,409,134


Simulations Plus Investor Relations
Ms. Renee Bouche, 661-723-7723
Hayden IR
Mr. Cameron Donahue, 651-653-1854

Release Summary

Simulations Plus today reported record results for the 1st quarter of fiscal year 2018 with net revenues over $7 million, an increase of $1.7 million.


Simulations Plus Investor Relations
Ms. Renee Bouche, 661-723-7723
Hayden IR
Mr. Cameron Donahue, 651-653-1854